Business Description
Vor Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US9290332074
Share Class Description:
VOR: Ordinary SharesTotal Employee Number:
76Compare
Compare
Traded in other countries / regions
VOR.USA Index Membership
Russell 2000Russell 2000Russell 3000 IPO Date
2021-02-05Description
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 162.02 | |||||
Equity-to-Asset | -0.42 | |||||
Debt-to-Equity | -0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 6.7 | |||||
3-Year EPS without NRI Growth Rate | 7.7 | |||||
3-Year FCF Growth Rate | 32.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 60.51 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.92 | |||||
9-Day RSI | 47.5 | |||||
14-Day RSI | 51.77 | |||||
3-1 Month Momentum % | 78.24 | |||||
6-1 Month Momentum % | 53.1 | |||||
12-1 Month Momentum % | -41.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 19.15 | |||||
Quick Ratio | 19.15 | |||||
Cash Ratio | 18.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -127.2 | |||||
Shareholder Yield % | -3.36 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | Neg. Equity | |||||
ROA % | 171.19 | |||||
ROIC % | -1498.89 | |||||
3-Year ROIIC % | 458.27 | |||||
ROC (Joel Greenblatt) % | -5421.3 | |||||
ROCE % | -43.52 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | 5.92 | |||||
Price-to-Owner-Earnings | 1.96 | |||||
EV-to-EBIT | -5.91 | |||||
EV-to-EBITDA | -5.91 | |||||
EV-to-FCF | -6.17 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.8 | |||||
Earnings Yield (Greenblatt) % | -16.92 | |||||
FCF Yield % | -10.57 |
GF Value™
Vor Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vor Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 64 days | ||
| Guidance call for 2026 | 2026-09-23 11:30 | In 14 days | ||
| Guidance call for 2026 | 2026-09-15 09:05 | In 6 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-14 | In 4 days | ||
| Guidance call for 2026 | 2026-09-09 11:20 | 25.10 (+1.41%) | ||
| Wells Fargo 21st Annual Healthcare Conference | 2026-09-08 08:00 | 25.05 (+3.64%) | ||
| Second quarter earnings results for 2026 | 2026-08-11 | 23.37 (+0.09%) | ||
| General meeting for 2026 | 2026-06-11 09:00 | 13.00 (-0.38%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 09:55 | 13.66 (-4.87%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 16.47 (-4.24%) |
Show
Entries
Press Release
| Subject | Date | ||
|---|---|---|---|
| Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases | 2022-03-22 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers